高危前列腺癌瘤内进化全景:PROGENY 研究的基因组与免疫参数
研究显示高危前列腺癌存在广泛体细胞突变与拷贝数异质性,突变负荷低(0.93/Mb),2 例为超突变且伴 MSH2、MSH6 错配修复蛋白缺失;转移性激素初治患者拷贝数改变负荷高于高危局限患者,Wnt/β-catenin 激活突变者 CD8+/FOXP3+ 比值低。
要点
- 高危前列腺癌存在广泛体细胞突变与拷贝数异质性,总体突变负荷低(0.93/Mb)。
- 2 例超突变患者伴 MSH2、MSH6 错配修复蛋白缺失。
- 转移性激素初治患者拷贝数改变负荷高于高危局限患者,与 Gleason 分级无关。
核心结论
- PROGENY 研究提供可用于研究肿瘤瘤内异质性的诊断平台。
- 临床高危前列腺癌的遗传学异常与肿瘤免疫浸润模式改变相关。
- Wnt/β-catenin 信号通路激活突变或错配修复缺陷可考虑作为免疫调节治疗的潜在生物标志物。
研究设计与样本
- 前瞻性单臂转化研究,采用靶向多区域前列腺穿刺活检。
主要发现
- 高危前列腺癌显示广泛的体细胞核苷酸变异与体细胞拷贝数改变异质性。
- 总体突变负荷低(0.93/Megabase),但 2 例患者为超突变,伴错配修复蛋白 MSH2 和 MSH6 缺失。
- 转移性激素初治前列腺癌(mHNPC)患者的体细胞拷贝数改变负荷高于高危局限前列腺癌(hrlPC)患者,且独立于 Gleason 分级。
- 突变罕见于所有区域,mHNPC 与 hrlPC 患者的突变频率相似;mHNPC 患者中可见含推定转移驱动基因的 3q26.2 和 3q21.3 局灶性富集。
- 单例患者中观察到平行进化,含 3 个独立克隆携带 β-catenin 激活突变;错配修复缺陷患者及 β-catenin 平行进化患者显示广泛瘤内与瘤间 T 细胞异质性及高炎症浸润。
临床怎么用
- 多区域穿刺活检平台可用于研究高危前列腺癌的瘤内异质性。
- Wnt/β-catenin 信号通路激活突变或错配修复缺陷可考虑作为免疫调节治疗的潜在生物标志物。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intratumoural heterogeneity (ITH) is well recognised in prostate cancer (PC), but its role in high-risk disease is uncertain. A prospective, single-arm, translational study using targeted multiregion prostate biopsies was carried out to study genomic and T-cell ITH in clinically high-risk PC aiming to identify drivers and potential therapeutic strategies. PATIENTS AND METHODS: Forty-nine men with elevated prostate-specific antigen and multiparametric-magnetic resonance imaging detected PC underwent image-guided multiregion transperineal biopsy. Seventy-nine tumour regions from 25 patients with PC underwent sequencing, analysis of mutations, copy number and neoepitopes combined with tumour infiltrating T-cell subset quantification. RESULTS: We demonstrated extensive somatic nucleotide variation and somatic copy number alteration heterogeneity in high-risk PC. Overall, the mutational burden was low (0.93/Megabase), but two patients had hypermutation, with loss of mismatch repair (MMR) proteins, MSH2 and MSH6. Somatic copy number alteration burden was higher in patients with metastatic hormone-naive PC (mHNPC) than in those with high-risk localised PC (hrlPC), independent of Gleason grade. Mutations were rarely ubiquitous and mutational frequencies were similar for mHNPC and hrlPC patients. Enrichment of focal 3q26.2 and 3q21.3, regions containing putative metastasis drivers, was seen in mHNPC patients. We found evidence of parallel evolution with three separate clones containing activating mutations of β-catenin in a single patient. We demonstrated extensive intratumoural and intertumoural T-cell heterogeneity and high inflammatory infiltrate in the MMR-deficient (MMRD) patients and the patient with parallel evolution of β-catenin. Analysis of all patients with activating Wnt/β-catenin mutations demonstrated a low CD8+/FOXP3+ ratio, a potential surrogate marker of immune evasion. CONCLUSIONS: The PROGENY (PROstate cancer GENomic heterogeneitY) study provides a diagnostic platform suitable for studying tumour ITH. Genetic aberrations in clinically high-risk PC are associated with altered patterns of immune infiltrate in tumours. Activating mutations of Wnt/β-catenin signalling pathway or MMRD could be considered as potential biomarkers for immunomodulation therapies. CLINICAL TRIALS.GOV IDENTIFIER: NCT02022371.
引用
- Linch M, Goh G, Hiley C, et al. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Ann Oncol. 2017. PMID: 28961847. doi:10.1093/annonc/mdx355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。